These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29651918)

  • 21. The effects of intravenous fosaprepitant and ondansetron in the prevention of postoperative nausea and vomiting in patients who underwent lower limb surgery: a prospective, randomized, double-blind study.
    Kakuta N; Kume K; Hamaguchi E; Tsutsumi R; Mita N; Tanaka K; Tsutsumi YM
    J Anesth; 2015 Dec; 29(6):836-41. PubMed ID: 26210166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized Controlled Pilot Study Comparing the Impact of Aprepitant and Fosaprepitant on Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecologic Cancer.
    Micha JP; Rettenmaier MA; Brown JV; Mendivil A; Abaid LN; Lopez KL; Goldstein BH
    Int J Gynecol Cancer; 2016 Feb; 26(2):389-93. PubMed ID: 26588232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.
    Maru A; Gangadharan VP; Desai CJ; Mohapatra RK; Carides AD
    Indian J Cancer; 2013; 50(4):285-91. PubMed ID: 24369195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of Polysorbate 80 in the Oncology Setting.
    Schwartzberg LS; Navari RM
    Adv Ther; 2018 Jun; 35(6):754-767. PubMed ID: 29796927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy.
    Ando Y; Hayashi T; Ito K; Suzuki E; Mine N; Miyamoto A; Oya M; Matsuda H; Isaji A; Nakanishi T; Imaizumi K; Shibata T; Okada T; Sakurai K; Naito K; Uyama I; Kawada K; Takahashi H; Yamada S
    Support Care Cancer; 2016 Feb; 24(2):871-878. PubMed ID: 26206077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Ruhlmann CH; Herrstedt J
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
    Lasseter KC; Gambale J; Jin B; Bergman A; Constanzer M; Dru J; Han TH; Majumdar A; Evans JK; Murphy MG
    J Clin Pharmacol; 2007 Jul; 47(7):834-40. PubMed ID: 17525168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
    Aapro M; Carides A; Rapoport BL; Schmoll HJ; Zhang L; Warr D
    Oncologist; 2015 Apr; 20(4):450-8. PubMed ID: 25795636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
    Ruhlmann CH; Christensen TB; Dohn LH; Paludan M; Rønnengart E; Halekoh U; Hilpert F; Feyer P; Kristensen G; Hansen O; Keefe D; Herrstedt J
    Lancet Oncol; 2016 Apr; 17(4):509-518. PubMed ID: 26952945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
    Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.
    Clark SM; Clemmons AB; Schaack L; Garren J; DeRemer DL; Kota VK
    J Oncol Pharm Pract; 2016 Jun; 22(3):416-22. PubMed ID: 25956421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of a Single 150-mg Intravenous Infusion of Fosaprepitant: Effects of Concentration and Infusion Time in Healthy Japanese Men.
    Azuma J; Fukase H
    Clin Pharmacol Drug Dev; 2013 Oct; 2(4):394-9. PubMed ID: 27121944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF].
    Uchiyama K; Yamada M; Shiiba Y; Kasazaki S; Suga K; Iwabuchi H; Asoda S; Uehara K
    Gan To Kagaku Ryoho; 2017 Jul; 44(7):585-589. PubMed ID: 28790262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids.
    Sun S; Schaller J; Placek J; Duersch B
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):509-13. PubMed ID: 23860958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of dexamethasone on vascular pain caused by the administration of fosaprepitant dimeglumine and epirubicin hydrochloride in patients with primary breast cancer].
    Kameda K; Kiba T; Ogawa Y; Kimoto S; Kajiume S; Okada Y; Morii N; Takahashi H; Ichiba Y; Yamashiro H
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1255-7. PubMed ID: 25335710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral neuropathy in non-Hodgkin's lymphoma patients receiving vincristine with and without aprepitant/fosaprepitant.
    Edwards JK; Bossaer JB; Lewis PO; Sant A
    J Oncol Pharm Pract; 2020 Jun; 26(4):809-813. PubMed ID: 31446866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the Use of Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients.
    Timaeus S; Elder J; Franco K
    J Pediatr Hematol Oncol; 2018 Oct; 40(7):527-531. PubMed ID: 29794645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.
    Takemoto H; Nishimura J; Komori T; Kim HM; Ota H; Suzuki R; Ikenaga M; Ikeda M; Yamamoto H; Satoh T; Hata T; Takemasa I; Mizushima T; Doki Y; Mori M;
    Int J Clin Oncol; 2017 Feb; 22(1):88-95. PubMed ID: 27465476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.